Short answer
ALUMIS INC. (ALMS) filed its fiscal 2024 10-K annual report with the SEC on Mar 19, 2025.
- Top risk flagged: Regulatory risk: FDA current cGMP compliance reliance on CMOs for manufacturing, with no own facilities impacting supply chain control
FY2024 key financial metrics · XBRL
- Net income
- −$294M
- −89.8% YoY
- EPS (diluted)
- −$10.38
- +85.6% YoY
- ROE
- -113.1%
- −158.8 pp YoY
- Operating cash flow
- −$255M
- −96.3% YoY
Source: XBRL data from the ALUMIS INC. (ALMS) FY2024 10-K on SEC EDGAR. USD.
ALUMIS INC. FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Clinical-stage biopharmaceutical developing precision TYK2 inhibition therapies for immune-mediated diseases
- New emphasis: Initiated Phase 1 trial of CNS-penetrant TYK2 inhibitor A-005 targeting MS and neurodegenerative diseases, reporting initial results in Dec 2024
- Strategic shift: Proposed merger with ACELYRIN, aimed at expanding late-stage pipeline and financial flexibility, expected ownership split ~55% Alumis / 45% ACELYRIN
- Quantitative highlight: Over 800 participants dosed with ESK-001; Phase 3 ONWARD global psoriasis trials ongoing with topline results expected Q1 2026
- Noteworthy fact: ESK-001 uniquely achieves maximal TYK2 inhibition with favorable safety, showing fewer skin toxicities than first-generation inhibitors
Risk Factors
- Regulatory risk: FDA current cGMP compliance reliance on CMOs for manufacturing, with no own facilities impacting supply chain control
- Macroeconomic threat: ongoing Ukraine and Israel conflicts potentially disrupting operations and financing access amid global instability
- Operational risk: dependency on CMOs for drug substance and product manufacturing, risking delays or quality issues in clinical supply
- Market disruption risk: competitive pressure to advance TYK2 inhibitors for PsO and SLE with Phase 3 readout expected Q1 2026
- Financial risk: accumulated deficit $658.6M with $288.3M cash as of Dec 31, 2024, requiring further financings or partnerships to continue operations
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.